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Summary
We describe a case of severe erythrocytosis caused by testosterone replacement therapy in a 66-year-old man affected 
with hypogonadotropic hypogonadism (HH) determining osteoporosis, resolved by switching to restoration therapy with 
clomiphene citrate. The patient complained fatigue, loss of libido and defective erections and a spontaneous vertebral 
fracture despite bisphosphonate therapy and vitamin D supplementation. The examinations proved isolated HH and 
he was therefore treated with testosterone gel with regression of specific manifestations but elevated hemoglobin 
and hematocrit values. Therefore, it was decided to switch to a restoration therapy with clomiphene citrate 25 mg/
die, which resulted in the resolution of symptoms without evident side effects. In a couple of months, the patient 
showed normalization of testosterone levels and increment of testicular volume. Since secondary hypogonadism is 
the consequence of an insufficient stimulation of the gonads by hypothalamic–pituitary axis, therapeutic approaches 
aimed to restore endogenous testosterone production should be considered in alternative to testosterone replacement, 
particularly if side effects intervene. Among these strategies, clomiphene citrate seems to have a high efficacy and safety 
profile also in the elderly with isolated HH and no evident pituitary lesion.
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Learning points:
 • Hypogonadism should always be assessed in patients with severe loss in BMD and undergo appropriate  
medical treatment.
 • In hypogonadotropic hypogonadism, more approaches are available other than testosterone replacement 
therapy alone.
 • In patients with severe late-onset central hypogonadism presenting with erythrocytosis even at low doses of 
replacement therapy, restoration therapy with clomiphene could prove to be an effective solution, particularly 
in patients with a reversible disruption of GNRH/gonadotropin functions.
 • Clomiphene citrate increases gonadotropin levels and testicular volume and should therefore be considered in 
hypogonadal men who wish to remain fertile.
Background
This case describes the successful use of an off-
label therapy for hypogonadotropic hypogonadism 
determining osteoporosis, in which replacement therapy 
was contraindicated due to erythrocytosis.
Case presentation
C R, a 66-year-old man, came to the endocrinologist’s 
atten tion for II grade obesity (he had gained 10 kg in 
the previous year) and symptoms of hypogonadism. He 
complained of low physical endurance, lack of libido 
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and erectile deficit and depressed mood; he was never 
interested in fathering a child.
In his past medical history, he reported two major 
surgery procedures due to a colon-sigma carcinoma 
(at the age of 55 years) and a kidney malignant tumor 
(at the age of 59 years); for none of the two tumors he 
received radiotherapy and/or chemotherapy. Moreover, 
he had essential hypertension. In 2012, osteoporosis 
was diagnosed (femoral T-score: −1.52; vertebral T-score: 
−3.2) without evidence of skeletal fractures, and he was 
therefore prescribed alendronate, calcium and 25OH 
vitamin D supplementation.
At the time of our evaluation, two years later, femoral 
BMD was further decreased by 4.8% and vertebral BMD by 
2%, compared with the previous examination. Moreover, 
the patient underwent an X-ray imaging for back pain that 
showed for the first time a thoracic vertebral deformation, 
and a 7-cm reduction in height was recorded. No 
familiarity for hypogonadism, pubertal delay, olfactory 
defect or osteoporosis was reported. He did not receive any 
medical treatment other than alendronate and vitamin D.
On physical examination, his height was 163 cm, 
weight: 97 kg, BMI: 36.5 kg/m2, PA: 140/90 mmHg, FC: 
76 bpm r, waist circumference: 123 cm; he showed normal 
virilization, regular penis dimension and conformation. 
He did not show gynecomastia. Testes were partially 
retractile and reduced in volume (12 mL right, 10 mL left) 
with normal consistency.
Investigation
The patient was therefore studied for hypogonadism 
and hormonal examinations proved HH: LH = 2.9 U/L; 
FSH = 3.1 U/L; PRL = 5.1 µg/L; total testosterone = 3.4 nmol/L 
(9.9–27.8). He had normal kidney and liver function, 
normal calcium and phosphorous metabolism and no 
other hormonal alteration.
Testicular ultrasound showed small size but normal 
structure. Brief Smell Identification Test (Sensonics, Inc., 
USA) demonstrated partial deficit in his olfactory ability 
(8 correct identifications out of 12 tested odorants, normal 
range for age and sex ≥9).
Genetic analyses were also performed using a targeted 
next-generation sequencing without proving any signifi-
cant allelic variant in the known causal genes for isolated 
HH: ANOS1(KAL1), FGFR1, PROKR2, PROK2, GNRHR, 
GNRH1, GNRH2; KISS1, KISS1R, TAC3, TACR3, HS6ST1 (1).
MR imaging showed normal pituitary and 
olfactory bulbs.
Treatment
In consideration of hormonal values and symptomatic 
osteoporosis, the patient started replacement therapy 
with testosterone gel 2%, 40 mg/day. Moreover, he was 
prescribed a tailored diet therapy.
During follow-up, C R demonstrated adequate 
androgen replacement with regression of the specific 
symptoms. Nevertheless, elevated hemoglobin and 
hematocrit values were noticed: Hb = 19.1 g/dL, 
Htc = 57.3%, total testosterone = 15.22 nmol/L.
Testosterone replacement therapy was then 
withdrawn and pulmonary causes of polyglobulia were 
excluded performing arterial blood gas analysis.
Since he was highly symptomatic and hemoglobin 
levels normalized, two months later, we started a new 
attempt with testosterone gel 2%, 10 mg/day, associated 
with anti-platelet therapy. Despite low testosterone doses, 
relapse of erythrocytosis promptly occurred (hematocrit 
52.2%) and hormone therapy was again withdrawn.
After informed consent, the patient was then switched 
to an off-label trial therapy using clomiphene citrate (CC) 
25 mg/die in order to avoid these severe side effects.
Outcome and follow-up
Within ten weeks, the patient showed a progressive 
increase and normalization of testosterone levels during 
the following nine months in association with normal 
gonadotropin levels (Table 1).
Moreover, this treatment was effective in stimulating 
testicular growth up to normal values (20 mL using 
Prader’s orchidometer), but no gynecomastia was seen.
In addition, a DEXA performed after 2  years of 
treatment showed an initial increase of bone mineral 
density, after the reported inefficacy of bisphosphonates 
and vitamin D supplementation. The patient also reported 
an improved quality of life and mood with restoration of 
libido and spontaneous erections.
Discussion
The European Male Aging Study has demonstrated the 
85% of late-onset hypogonadism to be hypogonadotropic 
(2). The current recommended therapy for both primary 
and secondary hypogonadism is testosterone replacement 
with proved beneficial effects on symptoms, even though 
it could induce infertility (3), hyperestrogenism (4) and 
erythrocytosis (5).
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Testosterone therapy causes erythrocytosis via 
increased erythropoietin and suppressed hepcidin (5) and 
during replacement therapy, hemoglobin and hematocrit 
must be carefully evaluated since an increment is a 
common untoward effect. This effect is known to be 
more common using testosterone enantate intramuscular 
injections rather than testosterone undecanoate or 
gel formulations due to a worse pharmacokinetic and 
dynamic profile (6).
In this case, we reported even low-dose testosterone 
gel replacement therapy proved to be impracticable; in 
such patients with highly symptomatic isolated central 
hypogonadism, alternative therapeutic approaches 
should be considered (7, 8).
Although CC is an off-label therapy in male, we 
proposed its use in order to obtain reversal of the HH 
since it is less likely to give supra-physiological peaks of 
testosterone. CC is indeed cheaper than hCG and is a 
Selective Estrogen Receptor Modulator (SERM) that acts 
by removing central negative feedback of estrogens, thus 
resulting in increased GnRH pulses, consequent LH and 
FSH elevations and testicular stimulation (Fig.  1). This 
mechanism of action is particularly useful in male obesity-
related HH with an increased aromatase activity of the 
visceral adipose tissue. Indeed, in our patient, CC proved 
to be effective in restoring eugonadism and avoiding the 
serious side effect given by exogenous hormone therapy 
despite the patient was over 65 years.
CC therapy in HH has been demonstrated to increase 
testosterone and to positively affect bone mineral 
density with a good safety profile after three years (9). 
Ta
b
le
 1
 
C
lin
ic
al
, b
io
ch
em
ic
al
 a
n
d
 r
ad
io
lo
g
ic
al
 fi
n
d
in
g
s 
d
u
ri
n
g
 t
h
e 
p
at
ie
n
t 
fo
llo
w
-u
p
.
  
LH
 
(U
/L
)
FS
H
 
(U
/L
)
 
TT
e
 (
n
m
o
l/L
; v
.n
. 9
–2
7)
 
E
2
 (
p
m
o
l/L
; v
.n
. <
12
1)
 
T-
sc
o
re
 v
e
rt
e
b
ra
l
 
T-
sc
o
re
 f
e
m
o
ra
l
Te
st
ic
u
la
r 
v
o
lu
m
e
 
(m
L)
 (
d
x/
sx
)
 
H
tc
 (
%
)
 
H
b
 (
g
/d
L)
P
S
A
 
(n
g
/m
L)
02
/2
01
4
2.
9
3.
1
3.
4
10
0
−
3.
3
−
1.
6
12
/1
0
45
.3
15
.3
1.
05
09
/1
5 
(t
es
to
st
er
o
n
e 
re
p
la
ce
m
en
t 
40
 m
g
/d
ie
)
0.
1
0.
1
15
.2
34
8
–
–
–
57
.3
19
.1
1.
63
01
/2
01
6 
(t
es
to
st
er
o
n
e 
re
p
la
ce
m
en
t 
10
 m
g
/d
ie
)
–
–
1.
68
83
–
–
–
52
.2
17
0.
99
04
/2
01
6 
(a
ft
er
 1
0 
w
ee
ks
 o
f 
re
st
o
ra
ti
o
n
 t
h
er
ap
y:
 C
lo
m
ip
h
en
e 
25
 m
g
/d
ie
)
5.
6
6.
1
7.
4
28
.3
−
3
−
1.
3
20
/2
0
47
.3
16
.3
0.
98
06
/1
6 
(r
es
to
ra
ti
o
n
 t
h
er
ap
y:
 
C
lo
m
ip
h
en
e 
25
 m
g
/d
ie
)
–
–
9.
28
12
7
–
–
–
46
.7
15
.8
1.
08
10
/2
01
6 
(r
es
to
ra
ti
o
n
 t
h
er
ap
y:
 
C
lo
m
ip
h
en
e 
25
 m
g
/d
ie
)
5.
8 
6.
7 
11
.0
8 
11
5 
– 
– 
20
/2
0 
46
.2
 
15
.2
 
1.
44
 
Figure 1
Mechanism of action of restoration therapies.
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Moreover, this SERM has been tested in male infertility 
with discordant results. However, even if its beneficial 
effects in idiopathic male infertility are still debated, it 
has a positive impact on hypogonadal infertile men (7) in 
contrast to testosterone replacement therapy that indeed 
reduces gonadal stimulation (6).
Interestingly, CC effectiveness has been questioned 
in elderly patients due to a limited efficacy compared 
with younger subjects. However, one study supporting 
this hypothesis was based on a small cohort of patients 
and the older subjects had elevated gonadotropin levels 
at baseline, whereas other papers documented only a 
minor symptomatic response attributable to end-organ 
disease as diabetes or other systemic pathologies (9, 10). 
Therefore, the lack of positive effect could be due to an 
underlying primary defect of the gonad or other causes 
affecting symptoms.
In conclusion, as secondary hypogonadism is 
the consequence of an insufficient stimulation of the 
gonads by hypothalamic–pituitary axis, new therapeutic 
approaches aimed to restore endogenous production of 
testosterone should be considered, especially in those 
patients in which testosterone replacement therapy is 
contraindicated due possible side effects. Among these 
strategies CC seems to have a high efficacy and safety 
profile (11). Thus, our study represents an additional 
support for the expansion of the CC indications to male 
HH, particularly when hypogonadism is obesity related.
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